<DOC>
	<DOCNO>NCT02131155</DOCNO>
	<brief_summary>This randomise , double-blind phase III trial perform patient head neck squamous cell carcinoma ( HNSCC ) . The objective trial compare efficacy safety afatinib ( BIBW 2992 ) placebo adjuvant therapy patient receive definitive chemo-radiotherapy .</brief_summary>
	<brief_title>LUX-Head &amp; Neck 4 : Afatinib ( BIBW 2992 ) Versus Placebo Treatment Head Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Histologically cytologically confirm locoregionally advanced head neck squamous cell carcinoma ( HNSCC ) , stage III IVb Unresected tumour prior chemoradiotherapy ( CRT ) Concomitant CRT complete prior randomisation After concomitant platinumbased CRT , evidence disease ( NED ) clinical radiographic examination Eastern cooperative oncology group ( ECOG ) performance status 0 1 Exclusion criterion : Patients smoke history less equal 10 pack year primary tumour site base tongue and/or tonsil Cancer nasopharynx , sinus , and/or salivary gland Prior treatment epidermal growth factor receptor ( EGFR ) target small molecule , EGFRtargeted antibody , and/or investigational agent HNSCC Known preexist Interstitial Lung Disease ( ILD ) Any past present history areca/betelnut chew derivative cumulative duration 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>